Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    « Previous 1  2  3  4  5  6  7  Next»
    Study title: DTPa-HBV-IPV-083
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41514
    Study title: DTPa-HBV-IPV-088
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41518
    Study title: DTPa-HBV-IPV-093
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41515
    Study title: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Leung TWT et al. Cancer, January 15, 2002, 421-7
    Active substance: FLUOROURACIL
    Study summary document link (including results):
    View full study record
    Document reference: 28272
    Study title: Fibrolamellar hepatocellular carcinoma in children and adolescents. Katzenstein HM et al. Cancer. 2003 Apr 15;97(8):2006-12
    Active substance: FLUOROURACIL
    Study summary document link (including results): 12673731.pdf
    View full study record
    Document reference: 28303
    Study title: Samoilenko I.G.,Yulish E.I., Gadetskaya S.G., Buchtiarov E.V.: New approach to treat pediatric patients suffering from bronchial asthma associated with intracellular infection. Biological Therapy (Ukraine), 2006, 4: 10-13 [IIT-publication]
    Active substance: Mucosa compositum
    Study summary document link (including results):
    View full study record
    Document reference: 40075
    Study title: Open Label, Multicenter, Phase IIIB, Follow up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis and Inactivated Poliovirus Antigens one Month after the 4th Hexavac® Vaccination in Healthy Children, who Participated in the NeisVac-C Non-Interference Study 216
    Active substance: N. meningitidis group C polysaccharide conjugated to tetanus toxoid adsorbed on Al3+
    Study summary document link (including results):
    View full study record
    Document reference: 41293
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43096
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43124
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43182
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43192
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43202
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43217
    Study title: Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36(5):1221-6 2002;(5):1221-1226.Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36(5):1221-6 2002;(5):1221-1226.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43100
    Study title: Hepatocellular carcinoma in children and adolescents: Results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. Katzenstein HM et al. J Clin Oncol. June 15, 2002, 2789-97
    Active substance: FLUOROURACIL
    Study summary document link (including results): 12065555.pdf
    View full study record
    Document reference: 28270
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43227
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43237
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43247
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43319
    Study title: The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcninoma. Zhang Z, Wu M, Liu Q. Chin J Oncol. July 6, 1999, 214-6
    Active substance: FLUOROURACIL
    Study summary document link (including results):
    View full study record
    Document reference: 28279
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: JMeza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: J
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43328
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43337
    Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43347
    Study title: Open label, randomised comparative assessment of the immunogenicity and reactogenicity of SmithKline Beecham's (SB's) diphteria/tetanus/acellular pertussis (DTPa) vaccine and SB's Hib with commercially available diphtheria/tetanus/whole cell pertussis (DTPw) and SB's Hib. Vaccines to be combined in the same syringe and administered to healthy infants as three consecutive doses at 2, 3 and 4 months of age.
    Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT)
    Study summary document link (including results):
    View full study record
    Document reference: 41137
    Study title: EUV07: A phase III, open, randomized, controlled, primary vaccination study to assess the immunogenicity and the safety of CP20/20/5/3DT-IPV-PRP~T and ACTAcel™ given concomitantly with OPV vaccine and TETRAct-Hib™ given concomitantly with OPV vaccine at 6, 10, 14 weeks of age. All infants receiving hepatitis B vaccine (Recomvax B™) at 0, 6, 14 weeks of age EUV06: Safety and immunogenicity of hepatitis B vaccine distributed by Aventis Pasteur Korea administered at 0-1-6 months when given in association with three Aventis Pasteur pertussis combination (1 whole cell and 2 acellular) vaccines administered at 2, 4 and 6 months in Mexican infants
    Active substance: Hepatitis B Surface Antigen
    Study summary document link (including results):
    View full study record
    Document reference: 47181
    Study title: Clinical study to assess the immunological memory induced by a primary course using different formulations of Hib conjugate vaccines in several combinations with acellular pertussis vaccines by giving one dose of unconjugated PRP co-administered with SB Biologicals¿ DTPa-HBV combined vaccine at 12-24 months of age in infants primed in study DTPa-HBV-037.
    Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT)
    Study summary document link (including results):
    View full study record
    Document reference: 41146
    Study title: Open, randomised, clinical study to evaluate the interference on the immunogenicity of vaccine antigens, when Haemophilus influenzae type b tetanus conjugate and combined diphtheria, tetanus, acellular pertussis vaccines are co-administered, either in one single or two separate injections as a primary vaccination course to healthy infants at 2, 4 and 6 months of age.
    Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT)
    Study summary document link (including results):
    View full study record
    Document reference: 41136
    Study title: Open clinical study to assess the safety of SmithKline Beecham Biologicals' Haemophilus influenzae type b conjugate vaccine mixed with SmithKline Beecham Biologicals' diphtheria, tetanus, tricomponent acellular pertussis vaccine and administered in one single injection, given as a primary vaccination course to healthy infants at 3, 4 and 5 months of age.
    Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT)
    Study summary document link (including results):
    View full study record
    Document reference: 41132
    Study title: Comparative safety and immunogenicity study of diphtheria, tetanus, acellular pertussis, poliomyelitis vaccine (DTacP-IPV) and diphtheria, tetanus, whole-cell pertussis, poliomyelitis vaccine (TETRACOQ®) given as a second booster to 4- to 7-year-old children
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41193
    Study title: Comparative safety and immunogenicity study of diphtheria, tetanus, acellular pertussis, poliomyelitis vaccine (DTacP-IPV) and diphtheria, tetanus, poliomyelitis vaccine (DT POLIO®) administered as a booster in children aged 8 to 12 years
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41197
    Study title: Concomitant administration of a Haemophilus influenzae type b - Hepatitis b vaccine with a diphtheria, tetanus, acellular pertussis, inactivated polio combination vaccine in healthy infants
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41191
    Study title: Diminution of the anti-polyribosylribito phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae Type b vaccine by concurrent inactivated poliovirus vaccination
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41205
    Study title: Large scale safety study of the DTacP-IPV {acellular TETRACOQ®) vaccine, administered in combination (one injection site) or in assocation two injection sites) with Haemophilus influenzae Type b vaccine (Act-HIB®) for primary and booster immunisation
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41203
    Study title: Randomised open trial of the safety and the immunogenicity of a combined dihtheria, tetanus, acellular pertussis and inactivated polio vaccine (DTacP-IPV) mixed with Haemophilus influenzae type b vaccine (Act-HIB®) given either at 3-5 and 12 or 2-4-6 and 13 months of age
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41190
    Study title: Safety and immunogenicity of a diphteria, tetanus, acellular pertussis, enhanced inactivated trivalent poliovirus vaccine administered separately or combined with Haemophilus influenzae type b vaccine, to healthy Chilean infants
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41188
    Study title: Safety and immunogenicity of PMSV diphtheria, tetanus, acellular pertussis, polio (DTacP-IPV) vaccine given mixed or separately with Haemophilus influenzae type b (Act-HIB®) vaccine, as a primary series. Comparison of three lots of DTacP-IPV vaccine given combined or separately with Act-HIB®
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41189
    Study title: Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen-to nineteen-month-old infants
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 41192
    Study title: Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization. ; Guan-Y-S. World Journal of Gastroenterology, 15 JUL 2004, Vol/Iss/Pg. 10/14 (2127-2129)Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization. ; Guan-Y-S. World Journal of Gastroenterology, 15 JUL 2004, Vol/Iss/Pg. 10/14 (2127-2129)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30291
    Study title: Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival. ; Uemura-S, T. European Journal of Pediatric Surgery, 1993, Vol /Iss/Pg. 3/1 (54-56)Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival. ; Uemura-S, T. European Journal of Pediatric Surgery, 1993, Vol /Iss/Pg. 3/1 (54-56)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30327
    Study title: Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases. Higuchi-T. Cancer , 1994, Vol/Iss/Pg. 73/9 (2259-2267)Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases. Higuchi-T. Cancer , 1994, Vol/Iss/Pg. 73/9 (2259-2267)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30258
    Study title: Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization. ;Jin-Wook-Chung, J. American Journal of Roentgenology, 1995, Vol/Iss/Pg. 165/2 (315-321)Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization. ;Jin-Wook-Chung, J. American Journal of Roentgenology, 1995, Vol/Iss/Pg. 165/2 (315-321)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30259
    Study title: Hepatocellular carcinoma outcomes based on indicated treatment strategy. ; Rose-A-T. American Surgeon, 1998, Vol/Iss/Pg. 64/12 (1128-1135)Hepatocellular carcinoma outcomes based on indicated treatment strategy. ; Rose-A-T. American Surgeon, 1998, Vol/Iss/Pg. 64/12 (1128-1135)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30260
    Study title: The role and limitation of living donor liver transplantation for hepatocellular carcinoma. ; Lo-C-M. Liver Transplantation, 2004, Vol/Iss/Pg. 10/3 (440-447)The role and limitation of living donor liver transplantation for hepatocellular carcinoma. ; Lo-C-M. Liver Transplantation, 2004, Vol/Iss/Pg. 10/3 (440-447)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30333
    Study title: A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B(12) binding capacity in a young Japanese female. ; Kanai-T. Japanese Journal of Clinical Oncology, 01 JUN 2004, Vol/Iss/Pg. 34/6 (346-351)A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B(12) binding capacity in a young Japanese female. ; Kanai-T. Japanese Journal of Clinical Oncology, 01 JUN 2004, Vol/Iss/Pg. 34/6 (346-351)
    Active substance: IOBITRITOL
    Study summary document link (including results):
    View full study record
    Document reference: 30213
    Study title: Extrahepatic metastases of hepatocellular carcinoma; KATYAL S; Radiology; 2000 vol.216 p.698 703Extrahepatic metastases of hepatocellular carcinoma; KATYAL S; Radiology; 2000 vol.216 p.698 703
    Active substance: IOVERSOL
    Study summary document link (including results):
    View full study record
    Document reference: 30411
    Study title: Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. ; Izumi-R. Hepato-Gastroenterology, 1996, Vol/Iss/Pg. 43/12 (1415-1420)Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. ; Izumi-R. Hepato-Gastroenterology, 1996, Vol/Iss/Pg. 43/12 (1415-1420)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30304
    Study title: Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. ;Czauderna-P. Pediatric Blood and Cancer, 2006, Vol/Iss/Pg. 46/7 (825-828)Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. ;Czauderna-P. Pediatric Blood and Cancer, 2006, Vol/Iss/Pg. 46/7 (825-828)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30306
    Study title: Preoperative Chemoembolization for Hepatocellular Carcinoma.02/12/2010Mario Morino. Journal of Surgical Oncology Supplement 3:91-93 (1993)Preoperative Chemoembolization for Hepatocellular Carcinoma.02/12/2010Mario Morino. Journal of Surgical Oncology Supplement 3:91-93 (1993)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30307
    Study title: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. ; Lau-W-Y. Lancet, 06 MAR 1999, Vol/Iss/Pg. 353/9155 (797-801)Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. ; Lau-W-Y. Lancet, 06 MAR 1999, Vol/Iss/Pg. 353/9155 (797-801)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30218
    Study title: Lipiodol computerized tomography: How sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? ; Ngan-H. British Journal of Radiology, 1990, Vol/Iss/Pg. 63/754 (771-775)Lipiodol computerized tomography: How sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? ; Ngan-H. British Journal of Radiology, 1990, Vol/Iss/Pg. 63/754 (771-775)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30281
    Study title: Liver transplantation in the therapy of hepatocellular carcinoma: A revision of our series. ; Lucena-de-la-Poza-J-L. Transplantation Proceedings, 2002, Vol/Iss/Pg. 34/1 (260-261)Liver transplantation in the therapy of hepatocellular carcinoma: A revision of our series. ; Lucena-de-la-Poza-J-L. Transplantation Proceedings, 2002, Vol/Iss/Pg. 34/1 (260-261)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30282
    Study title: Pulmonary embolism: A fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma. ;Czauderna-P. Journal of Pediatric Surgery, 2005, Vol/Iss/Pg. 40/10 (1647-1650)Pulmonary embolism: A fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma. ;Czauderna-P. Journal of Pediatric Surgery, 2005, Vol/Iss/Pg. 40/10 (1647-1650)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30315
    Study title: Safety of four acellular pertussis combination vaccines (Infantrix-IPV, Boostrix, Covaxis and repevax) given a booster dose to six-year-old Finnish children
    Active substance: purif tetan toxoid,purif dipht toxoid,purif pert toxoid,purif filamentous haemaggl,purif fimbriae (agglutinogens 2 & 3),purif pertactin (69kda membrane protein)-inact polio vacc
    Study summary document link (including results):
    View full study record
    Document reference: 41433
    Study title: Safety and immunogenicity of acellular pertussis combined with tetanus and diphtheria toxoids adsorbed and inactivated poliomyelitis vaccine (TdcP-IPV) in adolescents and adults compared to Td-mlPV and cP given separately in adolescents and compared to TdcP or Td given separately with IPV or cP in adults
    Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32)
    Study summary document link (including results):
    View full study record
    Document reference: 21208
    Study title: Liver transplantation in the therapy of hepatocellular carcinoma: A revision of our series.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39920
    Study title: Wiedermann D, Widermannova D, Lokaj J. Scripta Medica [Czech edition from Brno]. 1986; 59(7):415-424. Several parameters of cellular and humoral immune function in children with recurrent respiratory infections treated with Isoprinosine®.Wiedermann D, Widermannova D, Lokaj J. Scripta Medica [Czech edition from Brno]. 1986; 59(7):415-424. Several parameters of cellular and humoral immune function in children with recurrent respiratory infections treated with Isoprinosine®.
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30177
    Study title: Lipiodol computerized tomography: How sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma?
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39899
    Study title: Open Study to determine the concentration of telithromycin in the extracellular and intracellular compartments of middle ear fluid in children with acute otitis media or otitis media with spontaneous effusion after single oral administration of a telithromycin pediatric suspension
    Active substance: telithromycin
    Study summary document link (including results):
    View full study record
    Document reference: 41567
    Study title: Clin Nucl Med. 1995 Jul;20(7):601-4. Detection of a 2.1 cm hepatocellular carcinoma in an 11-year-old boy by Tl-201 chloride. Case presentation and correlative imaging findings. Kempf JS, Abdel-Dayem H. Clin Nucl Med. 1995 Jul;20(7):601-4. Detection of a 2.1 cm hepatocellular carcinoma in an 11-year-old boy by Tl-201 chloride. Case presentation and correlative imaging findings. Kempf JS, Abdel-Dayem H.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44553
    Study title: Samoilenko I.G.,Yulish E.I., Gadetskaya S.G., Buchtiarov E.V.: New approach to treat pediatric patients suffering from bronchial asthma associated with intracellular infection. Biological Therapy (Ukraine), 2006, 4: 10-13 [IIT-publication]
    Active substance: Lymphomyosot - Tropfen
    Study summary document link (including results):
    View full study record
    Document reference: 40057
    Study title: Comparative study of an acellular (P.M.sv.) and a whole cell (Wellcome) Pertussis vaccines com bined with Diphtheria and Tetanus vaccines in healthy infants according to 2 schedules in the U.K.
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41410
    Study title: DTPa-HBV-IPV-103
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41516
    Study title: A phase II, open-label, randomized, single-center, comparative study evaluating safety, tolerability and immunogenicity of three vaccinations of the DTPHib combined vaccine (Chiron Vaccines; now Novartis Vaccines) in comparison to separate vaccinations of DTP (Chiron Behring; now Novartis Vaccines) and Hib/AlPO4 (Chiron Vaccines; now Novartis Vaccines) vaccines, when administered to 2, 3, 4 months old healthy infants.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 48393
    Study title: A phase II, open-label, single-centre, singal-arm, extension study to evaluate the safety and immunogenicity of a booster vaccination of the DTPHib combined vaccine (Chiron Vaccines; now Novartis Vaccines) administered to 18-20 months old healthy infants who had previously received either DTPHib combined vaccine or separate administrations of DTP (Chiron Behring; now Novartis Vaccines) and Hib/AlPO4 (Chiron Vaccines; now Novartis Vaccines) vaccines at 2, 3 and 4 months of age.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 48394
    Study title: Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish].
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43268
    Study title: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43274
    « Previous 1  2  3  4  5  6  7  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 08:17:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA